Previous 10 | Next 10 |
April 1, 2020 Palm Beach, FL – April 1, 2020 – The World House has called on U.S. health regulators to expedite potential therapies aimed at treating COVID-19 amid the fast-spreading coronavirus outbreak, saying it could lead to a breakthrough while a vaccine is still un...
AbbVie (NYSE: ABBV ) donates $35M to support COVID-19 relief efforts. Shares down 2% premarket. More news on: AbbVie Inc., Mallinckrodt plc, CytoDyn Inc., Healthcare stocks news, Stocks on the move, Read more ...
VANCOUVER, Washington, April 01, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting companies which recently presented at it’s NEXT SUPER STOCK investor conference series that are making news this week. FaceBank Group (OTC: FBNK) Merg...
March 31, 2020 Palm Beach, FL – March 31, 2020 – The World Health Organization has urged people and nations to avoid spreading the pathogen in the current global health crisis while the search for treatments continues at a its frenzied pace, but even at their most effect...
CytoDyn ( OTCQB:CYDY ) has completed a new non-dilutive convertible debt offering of $15M. More news on: CytoDyn Inc., Healthcare stocks news, , Read more ...
CytoDyn ( OTCQB:CYDY ) announces that the FDA has provided clearance for initiation of a Phase 2 trial with leronlimab to treat COVID-19 patients with mild to moderate indications. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
VANCOUVER, Washington, March 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
VANCOUVER, Washington, March 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
VANCOUVER, Washington, March 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...